Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2019

In 2019, Fate Therapeutics, Inc.'s disclosed short interest ran from 12.95% of shares outstanding on 15 Jan 2019 to 11.99% on 31 Dec 2019, a change of -0.96 percentage points. The year's high was 15.54% on 30 Sep 2019 and its low 11.99% on 31 Dec 2019, averaging 13.50% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.60 days on 31 Oct 2019. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2019

2019 in figures

Start of year
12.95% (15 Jan 2019)
End of year
11.99% (31 Dec 2019)
Change
-0.96 pp
High
15.54% (30 Sep 2019)
Low
11.99% (31 Dec 2019)
Average
13.50%
Highest days to cover
19.60 (31 Oct 2019)
SEC filings marked
8

Every report in 2019

Fate Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201912.95%10.91
31 Jan 201912.55%12.25
15 Feb 201913.19%15.70
28 Feb 201913.07%12.02
15 Mar 201912.73%10.8410-K filed, results (8-K)
29 Mar 201912.76%13.45
15 Apr 201913.61%15.10
30 Apr 201914.74%15.27
15 May 201914.27%11.3710-Q filed, results (8-K)
31 May 201912.70%9.46
14 Jun 201912.83%11.28
28 Jun 201913.96%10.07
15 Jul 201913.40%11.09
31 Jul 201913.51%14.46
15 Aug 201914.42%11.7610-Q filed, results (8-K)
30 Aug 201914.34%16.28
13 Sep 201915.18%8.62
30 Sep 201915.54%12.35
15 Oct 201914.88%12.17
31 Oct 201914.48%19.60
15 Nov 201912.53%13.4610-Q filed, results (8-K)
29 Nov 201912.40%16.42
13 Dec 201912.02%4.60
31 Dec 201911.99%12.72

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.